Enrolment Has Set by Vaxlnnate Corporation for Phase I Trial

VaxInnate Corporation introduced that enrollment has set out using Phase I clinical trial to assess VAX161, its novel H5 vaccine candidate in development regarding the protection against pandemic avian influenza or bird flu. VaxInnate is definitely a biotechnology firm pioneering discovery technology for producing novel vaccines.

The study has been conducted under VaxInnate's contract with the Biomedical Advanced Research and Development Authority, section of the U.S. Department of Health and Human Services. The trial would examine the security and immunogenicity of VAX161.

The dose-ranging survey evaluates the security and immunogenicity of a couple of doses of VAX161 given by intramuscular injection 3 weeks apart at six dose stages varying from 14th August to 12th August. The research has 250 healthy men and women aged 18-49 years. The study is predicted to yield data that could allow VaxInnate to select the acceptable dose of VAX161 for further development. Achievements are anticipated late this year. "The purpose of this research is to optimize the medicine, driven by immunogenicity and overall safety of VAX161," said David Taylor, MD, Chief Medical Officer.